Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Lineage Cell Therapeutics, Inc. | Financial_Report.xls |
| EX-10.1 - EXHIBIT 10.1 - Lineage Cell Therapeutics, Inc. | ex10_1.htm |
| 10-Q - BIOTIME INC 10-Q 6-30-2011 - Lineage Cell Therapeutics, Inc. | form10q.htm |
| EX-31 - EXHIBIT 31 - Lineage Cell Therapeutics, Inc. | ex31.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of BioTime, Inc. (the “Company”) for the quarter ended June 30, 2011 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Michael D. West, Chief Executive Officer, and Robert W. Peabody, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 9, 2011
|
/s/ Michael D. West
|
|
|
Michael D. West
|
|
|
Chief Executive Officer
|
|
| /s/ Robert W. Peabody | |
| Robert W. Peabody | |
| Chief Financial Officer |